Showing results (121-130 of 831) with videos related to
Sort By:
Pageof 84
Expert Review of Anticancer Therapy|December 22, 2007
Targeted therapy in chronic myeloid leukemiaElias Jabbour, Jorge E Cortes, Hady Ghanem, et al.Current Oncology Reports|June 7, 2012
Philadelphia-positive acute lymphoblastic leukemia: current treatment optionsTheresa Liu-Dumlao, Hagop Kantarjian, Deborah A Thomas, et al.Expert Opinion on Biological Therapy|March 17, 2015
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomasMaro Ohanian, Hagop Kantarjian, Daniel Guy, et al.Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studiesHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.Blood|March 18, 2006
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaKensuke Kojima, Marina Konopleva, Teresa McQueen, et al.American Journal of Hematology|May 23, 2013
Recent advances in de novo CD5+ diffuse large B cell lymphomaPreetesh Jain, Luis E Fayad, Andreas Rosenwald, et al.Leukemia|April 30, 2026
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapiesYun Wang, Chunhua Li, Robert Peter Gale, et al.Mayo Clinic Proceedings|March 11, 2004
Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphomaIrene M Ghobrial, Nancy D Bone, Mary J Stenson, et al.Cancer|January 20, 2011
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Susan O'Brien, et al.Pageof 84